What are you looking for?
Start main content
Professor CHAN Lik Yuen, Henry

Professor CHAN Lik Yuen, Henry

Associate Dean (External Affairs)

Professor, Department of Medicine and Therapeutics

CUHK Employment
  • Associate Dean (External Affairs), Faculty of Medicine
  • Director, Office of Global Engagement, Faculty of Medicine
  • Professor, Department of Medicine and Therapeutics
  • Director, Centre for Liver Health
  • Associate Head, Shaw College

  • Gastroenterology and Hepatology


Education & Qualifications




Research Interests
  • Viral hepatitis
  • Liver fibrosis
  • Liver cancer
  • Anti-viral therapy
  • Fatty liver disease
Additional Information


Award & Honour

  • Highly Cited Researcher (Cross Field), Clarivate Analytics, 2018
  • Honorary Visiting Professor, Ludwig-Maximilians-Universtat Munchen (University of Munich), 2018
  • Guangdong Province Science & Technology Award - First-class Award, 2018
  • Okuda Lectureship Award, Asia Pacific Digestive Week, 2018
  • Chainuvati Lecturer, Thai Association for the Study of the Liver, Thailand, 2018
  • Excellent Research Award, Food and Health Bureau, Hong Kong, 2014
  • National Award for Science and Technology Progress 2012 - Second-class, 2012
  • MoE Higher Education Outstanding Scientific Research Output Award (Scientific and Technological Progress Award) - First-class, Ministry of Education, 2012
  • Sir David Todd Lectureship, Hong Kong College of Physicians, 2011
  • Croucher Senior Medical Research Fellowship, The Croucher Foundation, Hong Kong, 2011
  • JGH Emerging Leader Lectureship Award, Asia Pacific Digestive Week, 2010
  • Excellent Research Award (Clinical Studies), Food and Health Bureau, Hong Kong, 2010
  • Association of Southeast Asian Institutions of Higher Learning -Scopus Young Scientist Award, 2008
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians, 2008
  • Young Investigator Award, Asian Pacific Association for the Study of the Liver, 2008
  • Ten Outstanding Young Persons Award, Hong Kong, 2008 


Professional Service

  • Chairman, Strategic Technical Advisory Committee for Viral Hepatitis, Western Pacific Regional Office of World Health Organization
  • Council member, Hong Kong Association for the Study of Liver Diseases

  • Deputy Chief of Service, Department of Medicine and Therapeutics, Prince of Wales Hospital

  • Associate editor, Hepatology International
  • Associate editor, Seminar of Liver Diseases


Academic Engagement in CUHK

  • Programme Director, Certificate in Professional Medical Communication
  • Associate Programme Director, Master of Science in Gastroenterology
  • Supervisor, MPhil and PhD in Medical Sciences
  • Lecturer, Diploma in Advances in Medicine
Selected Publications
  1. VWS Wong, GLH Wong, RS Chan, SST Shu, BH Cheung, LS Li, AML Chim, CK Chan, JK Leung, WCW Chu, J Woo, HLY Chan. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018;69:1349-56.
  2. K Agarwal, M Brunetto, WK Seto, YS Lim, S Fung, P Marcellin, SH Ahn, N Izumi, WL Chuang, H Bae, M Sharma, HLA Janssen, CQ Pan, M Celen, N Furusyo, Shalimar, KT Yoon, H Trinh, JF Flaherty, A Gaggar, A Lau, AL Cathcart, L Lin, N Bhardwaj, V Suri, GM Subramanian, E Gane, M Buti, HLY Chan. 96 weeks treatment of tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of chronic hepatitis B virus infection. J Hepatol 2018;68:672-81.
  3. TCF Yip, GLH Wong, VWS Wong, YK Tse, GCY Lui, KLY Lam, HLY Chan. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol 2018;68:63-72.
  4. HLY Chan, S Fung, WK Seto, WL Chuang, CY Chen, HJ Kim, AJ Hui, HLA Janssen, A chowdhury, TY Tsang, R Mehta, E Gane, JF Flaherty, B Massetto, A Gaggar, KM Kitrinos, L Lin, GM Subramanian, JG McHutchison, YS Lim, SK Acharya, K Agarwal, GS-US-320-0110 investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016;1:185-95.
  5. HLY Chan, SH Ahn, TT Chang, CY Peng, D Wong, CS Coffin, SG Lim, PJ Chen, HLA Janssen, P Marcellin, L Serfaty, S Zeuzem, D Cohen, L Critelli, D Xu, M Wind-Rotolo, E Cooney, and the LIRA-B study team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis: a randomized phase 2b study (LIRA-B). J Hepatol 2016;64:1011-9.
  6. VWS Wong, GLH Wong, JCL Yeung, CYK Fung, JKL Chan, ZHY Chang, CTY Kwan, HW Lam, J Limquiaco, AML Chim, HLY Chan. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology 2016;63:754-63.
  7. P Marcellin, SH Ahn, X Ma, FA Caruntu, WY Tak, M Elkashab, WL Chuang, SG Lim, F Tabak, R Mehta, J Petersen, GR Foster, L Lou, EB Martins, P Dinh, A Corsa, P Charuworn, GM Subramanian, H Reiser, HW Reesink, S Fung, SI Strasser, H Trinh, M Buti, GB Gaeta, AJ Hui, G Papatheodoridis, R Flisiak, HLY Chan, on behalf of the study 149 investigators. Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134-44.
  8. Y Tian, VWS Wong, GLH Wong, W Yang, H Sun, J Shen, JH Tong, MY Go, YS Cheung, PB Lai, M Zhou, G Xu, YH Huang, J Yu, KF To, ASF Cheng, HLY Chan. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res 2015;75:4803-16.
  9. VWS Wong, GLH Wong, DKW Yeung, TKT Lau, CKM Chan, AML Chim, JM Abrigo, RSM Chan, J Woo, YK Tse, WCW Chu, HLY Chan. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015;62:182-9.
  10. HLY Chan, CK Chan, AJ Hui, S Chan, F Poordad, TT Chang, P Mathurin, JF Flaherty, L Lin, A Corsa, A Gaggar, GM Subramanian, JG McHutchison, S Lee, EJ Gane. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014;146:1240-8.